ArticleBMC health services research2023

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.

Juthamas Prawjaeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.